Modality
Small Molecule
MOA
MALT1i
Target
BCMA
Pathway
Sphingolipid
Schizophrenia
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
Oct 2019
→ May 2028
Phase 2Current
NCT06842661
1,874 pts·Schizophrenia
2022-11→2028-05·Terminated
NCT03013938
572 pts·Schizophrenia
2019-10→2025-07·Not yet recruiting
2,446 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-019mo agoPh3 Readout· Schizophrenia
2028-05-072.1y awayPh3 Readout· Schizophrenia
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-07-01 · 9mo ago
Schizophrenia
Ph3 Readout
2028-05-07 · 2.1y away
Schizophrenia
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06842661 | Phase 2/3 | Schizophrenia | Terminated | 1874 | HbA1c |
| NCT03013938 | Phase 2/3 | Schizophrenia | Not yet recr... | 572 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA |